Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide vs APC for GAVE-Related Anaemia in Cirrhosis (TAG Trial)
NCT06772480Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of thalidomide in gastric antral vascular ectasia (GAVE) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Mean increase in hemoglobin levels from baseline at 4 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
gastric antral vascular ectasia (GAVE)
Beyond the preview
Go deeper on NCT06772480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772480.